Results note: Third quarter of 2017

Tuesday, 14 November 2017.

Reig Jofre keeps sales stable, reduces net debt and continues to invest in manufacturing capacity to attend expected increase of demand

  • Reig Jofre closed the first nine month of the year with turnover of 119,6 M€ (+0.2%)

  • The good performance of the lines of injectables (+ 21%), dermatology (+ 10%) and respiratory (+ 14%) counteracted the still slow recovery of the lines of antibiotics (-9%) and nutritional supplements (-9%)

  • Reig Jofre closed the third quarter of 2017 with EBITDA of 9.2 M € compared to 11.5 M € in the same period of the previous year, directly motivated by the increase in personnel costs due to investments in manufacturing capacity in three of its four plants, as a result of the growth in demand in the dermatology and injectable lines; the investment in expansion projects in new markets in the line of antibiotics, and the non-reduction of the workforce linked to this line despite the fall in sales and in anticipation to the beginning of the recovery

  • Despite the above, a better financial result and a lower tax item slightly corrected the impact on the net result, which stood at 3.2 M € versus 5.0 M € in the same period of 2016

  • At the end of September, net financial debt was reduced by 37% to € 13.8 million, below 1 time EBITDA, compared to 1.9 times at the end of 2016

Download the full document (PDF)

This site uses only technical third party cookies to provide better service, when browsing this website you agree to its use. See ourlegal advice. Agree

Our website is protected by DMC Firewall!